Abstracts tagged "aquaporin"

Abstract Number: 143 • ACR/ARHP Annual Meeting 2018
Aquaporin 3 (AQP3) Protein Is Highly Expressed in Psoriatic Plaques and AQP3 Gene Expression Strongly Induced By IL-23 in CD4+ Th17 Cells
Ananta Paine¹, Maria de la Luz Garcia-Hernandez², Benjamin D. Korman², Judilyn Duculan³, Mayte Suarez-Farinas⁴, James G. Krueger³ and Christopher T. Ritchlin², ¹Department of Medicine, Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ²Division of Allergy/Immunology and Rheumatology and Center for Musculoskeletal Research, School of Medicine and Dentistry, University of Rochester Medical School, Rochester, New York, USA, Rochester, NY, ³Laboratory for Investigative Dermatology, Rockefeller University, New York City, New York, USA, New York City, NY, ⁴Icahn School of Medicine at Mount Sinai, New York City, New York, USA, New York City, NY
Background/Purpose: Th17, a subset of CD4+ helper T cells, provides protection against pathogens and malignancies, but also promotes immune-mediated-inflammation in a range of disorders including…
Abstract Number: 112 • Pediatric Rheumatology Symposium 2017
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder
Sabrina Gmuca¹, Amy T. Waldman², Pamela F. Weiss³ and Jeffrey S. Gerber², ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²The Children's Hospital of Philadelphia, Philadelphia, PA, ³Division of Rheumatology, Center for Pediatric Clincial Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: First-line use of rituximab for neuromyelitis optica spectrum disorder (NMOSD) is common but the benefits of early immunosuppression remain unclear. We aimed to determine…
Abstract Number: 1348 • ACR/ARHP Annual Meeting 2016
Neuromyelitis Optica: Patient Characteristics and Treatment Patterns Among Rheumatologists Versus Non-Rheumatologists
Sabrina Gmuca¹, Rui Xiao², Amy T. Waldman³, Jeffrey S. Gerber⁴ and Pamela F. Weiss⁵, ¹Pediatric Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ²Department of Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ³Pediatric Neurology, The Children's Hospital of Philadelphia, Philadelphia, PA, ⁴The Children's Hospital of Philadelphia, Philadelphia, PA, ⁵Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Neuromyelitis optica (NMO) is an immune-mediated inflammatory disorder of the central nervous system that has been associated with systemic autoimmunity often cared for by…
Abstract Number: 3229 • ACR/ARHP Annual Meeting 2016
Bone Morphogenetic Protein 6 Receptor Inhibition Restores Salivary Gland Function in a Mouse Model of Primary Sjögren’s Syndrome
Hongen Yin¹, Lovika Kalra¹, Arif Karim¹, Zhennan Lai¹, Maria Guimaro¹, Lauren Aber¹, Bill Swaim¹, Sandra Afione¹, Alexandria Voigt², Cuong Nguyen³, Paul Yu⁴, Donald Bloch⁵ and John A. Chiorini¹, ¹Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ²Department of Pathology and Infectious Diseases, University of Florida, Gainesville, FL, ³Department of Pathology and Infectious Diseases, University of Florida, Bethesda, MD, ⁴Cardiovascular Division, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁵Center for Immunology and Inflammatory Diseases and the Division of Rheumatology, Allergy, and Immunology of the Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Methods: Results: Elevated BMP6 was found in 63/80 (78.8%) of pSS patients examined in this study. In humans, ALK2 and ALK3 receptors…
Abstract Number: 1056 • ACR/ARHP Annual Meeting 2015
Aquaporin Gene Therapy Corrects Bone Morphogenetic Protein 6 Associated Exocrine Gland Dysfunction in Mouse Model of Sjögren’s Syndrome
Hongen Yin¹, Zhennan Lai², Javier Cabrera-Perez³, Patricia Glenton⁴, Ankur Patel⁵, William Swaim⁵, Changyu Zheng⁵, Maria Guimaro⁵, Sandra Afione⁶, Cuong Nguyen⁵, Fred Nyberg⁷ and John A. Chiorini², ¹NIDCR, NIH, Bethesda, MD, ²Mptb, NIH/NIDCR, Bethesda, MD, ³Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Bethesda, MD, ⁴Department of Pathology and Infectious Diseases, University of Florida, Gaineville, FL, ⁵Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, ⁶National Institute of Dental and Craniofacial Research, Bethesda, MD, ⁷Department of Pharmaceutical Bioscience, Division of Biological Research on Drug Dependence, Uppsala University, Uppsala, MD, Sweden
Background/Purpose: Loss of secretory epithelial function is a hallmark of primary Sjögren’s syndrome (pSS). Previously we reported that bone morphogenetic protein 6 (BMP-6) inhibits cell volume…